Tradestie Institutional Equity Comparison Engine

SRZN vs KTTA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

SRZN Overall Edge

SRZN Captures Institutional Edge (2โ€“1 Pillars ยท 4โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Surrozen, Inc. Common (SRZN) driven by superior Momentum & Technical, Options & Structure while KTTA counters with relative strength in Growth & Margin. Fundamentally, SRZN trades at N/M Forward P/E with -485.4% operating margin (+408.6% YoY revenue) versus KTTA at N/M Forward P/E and 0.0% operating margin (+1498.1% YoY). In options structure, SRZN sits in CONSOLIDATION (13th %ile IV; Dealer Gamma Walls on Pro) against KTTA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
SRZN N/M vs KTTA N/M Fwd P/E
Growth & Margin Winner KTTA
Op Margin -485.4% vs 0.0% ยท YoY +408.6% vs +1498.1%
Momentum & Technical Winner SRZN
1Y +110.8% vs +0.6% ยท 52W Pos 63% vs 11%
Options & Structure Winner SRZN
CONSOLIDATION (13th %ile IV) vs UNCLASSIFIED (N/A IV)
SRZN NASDAQ
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$28.46
-7.21% 1D
Market Cap $642.7M
1M Return +10.52%
1Y Return +110.81%
Forward P/E N/M
Unified AI Score
36.0 / 100 SELL
Tech 15.0 Fund 42.0 Flow 65.0 Mom 50.0
KTTA NASDAQ
Pasithea Therapeutics Corp. Common Stock
Pharmaceutical Preparations
$0.48
-0.48% 1D
Market Cap $17.7M
1M Return +7.52%
1Y Return +0.59%
Forward P/E N/M
Unified AI Score
42.1 / 100 HOLD
Tech 20.0 Fund 40.0 Flow 50.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: SRZN +110.81% KTTA +0.59% Spread: +110.22 pp (SRZN Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period SRZN Revenue KTTA Revenue SRZN Op. Margin KTTA Op. Margin Margin Edge
FY2021 N/A $0M N/A -29925.7% KTTA
FY2022 $10M $0M -354.7% -2587.3% SRZN
FY2024 $10M N/A -239.7% N/A SRZN
FY2025 $0M N/A -1210.6% N/A SRZN

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: SRZN (4) vs KTTA (3)
Institutional Metric SRZN KTTA Criterion Row Winner
Market Capitalization Scale $642.7M $17.7M Larger Scale SRZN
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +408.6% +1498.1% Higher Growth KTTA
Operating Margin (TTM) Profitability -485.4% 0.0% Higher Margin KTTA
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -62.8% -88.8% Higher ROE SRZN
52-Week Range Position Momentum 63% ($13โ€“$38) 11% ($0โ€“$2) Stronger Trend SRZN
Beta / 30D Volatility Risk Regime 1.29ฮฒ ยท 73% Vol 0.68ฮฒ ยท 185% Vol Lower Realized Risk SRZN
Unified Institutional Score Composite Signal 36.0 / 100 (SELL) 42.1 / 100 (HOLD) Higher Composite KTTA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full SRZN vs KTTA Buy Guide
SRZN CONSOLIDATION
41d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 13th %ile
IV Regime Compressed (<25th %ile)
Live SRZN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
KTTA UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live KTTA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither SRZN nor KTTA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.